Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 2
2001 1
2002 3
2004 5
2005 6
2006 4
2007 10
2008 5
2009 5
2010 14
2011 10
2012 9
2013 7
2014 7
2015 7
2016 9
2017 8
2018 11
2019 14
2020 15
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

143 results
Results by year
Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: perol d. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.
Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, Cassier P, Eberst L, Steineur MP, Kazes M, Perol M, Michallet AS, Rey P, Erena-Penet AS, Morel A, Brahmi M, Dufresne A, Tredan O, Chvetzoff G, Fayette J, de la Fouchardiere C, Ray-Coquard I, Bachelot T, Saintigny P, Tabutin M, Dupré A, Nicolas-Virelizier E, Belhabri A, Roux PE, Fuhrmann C, Pilleul F, Basle A, Bouhamama A, Galvez C, Herr AL, Gautier J, Chabaud S, Zrounba P, Perol D, Blay JY. Assaad S, et al. Among authors: perol d. Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7. Eur J Cancer. 2020. PMID: 32540204 Free PMC article.
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Cleaud AL, Robain M, Courtinard C, Cailliot C, Perol D, Delaloge S. Gobbini E, et al. Among authors: perol d. Eur J Cancer. 2018 Jun;96:17-24. doi: 10.1016/j.ejca.2018.03.015. Epub 2018 Apr 13. Eur J Cancer. 2018. PMID: 29660596
Surgery in reference centers improves survival of sarcoma patients: a nationwide study.
Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S; NETSARC/REPPS/RESOS and French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) Networks. Blay JY, et al. Among authors: perol d. Ann Oncol. 2019 Jul 1;30(7):1143-1153. doi: 10.1093/annonc/mdz124. Ann Oncol. 2019. PMID: 31081028 Free PMC article.
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Courtinard C, Perol D, Robain M, Delaloge S. Deluche E, et al. Among authors: perol d. Eur J Cancer. 2020 Apr;129:60-70. doi: 10.1016/j.ejca.2020.01.016. Epub 2020 Mar 2. Eur J Cancer. 2020. PMID: 32135312
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY; ProfiLER investigators. Trédan O, et al. Among authors: perol d. Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080. Ann Oncol. 2019. PMID: 30865223 Free article.
Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study.
Delrieu L, Pialoux V, Pérol O, Morelle M, Martin A, Friedenreich C, Febvey-Combes O, Pérol D, Belladame E, Clémençon M, Roitmann E, Dufresne A, Bachelot T, Heudel PE, Touillaud M, Trédan O, Fervers B. Delrieu L, et al. Among authors: perol d. JMIR Mhealth Uhealth. 2020 Jan 28;8(1):e12306. doi: 10.2196/12306. JMIR Mhealth Uhealth. 2020. PMID: 32012082 Free PMC article.
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.
Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, Azria D, Beckendorf V, Suchaud JP, Bernier V, Perol D, Carrie C. Pommier P, et al. Among authors: perol d. Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):759-769. doi: 10.1016/j.ijrobp.2016.06.2455. Int J Radiat Oncol Biol Phys. 2016. PMID: 27788949 Clinical Trial.
PARP Inhibitors in Ovarian Cancer. Reply.
Ray-Coquard I, Pérol D, Pujade-Lauraine E. Ray-Coquard I, et al. Among authors: perol d. N Engl J Med. 2020 Apr 16;382(16):1574-1575. doi: 10.1056/NEJMc2000644. N Engl J Med. 2020. PMID: 32294365 No abstract available.
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Pérol M, et al. Among authors: perol d. J Clin Oncol. 2012 Oct 1;30(28):3516-24. doi: 10.1200/JCO.2011.39.9782. Epub 2012 Sep 4. J Clin Oncol. 2012. PMID: 22949150 Clinical Trial.
143 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page